Tramadol, buy tramadol, antibiotics, Weight Loss drugs, weight loss herbs, weight loss herbal formula, weight loss, hair loss, hair growth, baldness, Rx Online, pharmaceuticals, DHEA, Lutein, Prescription, Prescription drug, prescription medications, interferon.

DreamPharm Products:

Lutein-20||Herbs for headache, fever, and migraine || Milk thistle||Saw palmetto|| Triple B Super Vision||Garlic, Ginger, and Grapeseed Extract|| Ginseng and Ginkgo||Hair Million|| DHEA||Coenzyme Q10|| Sleep Aid herbal formula - natural sleep aid||Herbal Breath - herbs for bad breath problems.|| Weight loss herbal formula for menopause and pms||Ginkgo biloba|| Colon cleansing, Laxative||ViaVita, Lecithin for healthy liver

Fatty acids resources:

Pathogen research abs 1 || Pathogen research abs 2 || Pathogen research abs 3 || Pathogen research abs 4 || Pathogen research abs 5 || Hormone and endocrine research abs 1 || Hormone and endocrine research abs 2 || Hormone and endocrine research abs 3 || Hormone and endocrine research abs 4 || Hormone and endocrine research abs 5 || Follicle and follicular cells research abs 1 || Interferon research abs 1

msic.med.osaka-cu.ac.jp

Interferon (IFN) therapy decreases the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV). One hundred and fifty-nine consecutive patients who underwent liver resection for HCV-related HCC were studied. In 17 (group 1) of the 159 patients, HCC was detected during or after IFN therapy. The incidences of recurrence after surgery in the group 1 patients and the other 142 patients (group 2) were compared. Eight patients had a complete response to IFN, 4 had a partial response, and 5 had no response. The proportion of patients without HCV viremia was significantly higher in the group 1 patients (P < 0.0001). The tumor-free survival rate was significantly higher in the group 1 patients (P = 0.0010). By multivariate analysis of various risk factors for recurrence, no previous IFN was a significant independent risk factor for recurrence (risk ratio = 6.336; 95%CI, 1.512 - 26.50). The patients with HCC who underwent IFN therapy previously are good candidates for liver resection because recurrence after the operation was rarely observed.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11173545&dopt=Abstract

Pathol Oncol Res. 1996;2(1-2):59-62.
The Effect Of Long Term and High Dose Interferon Treatment In Chronic Hepatitis C.

Horvath G, Stotz G, Tolvaj G, Osztrogonacz H, David K.

Central Hospital of the Ministry of the Interior, 1st Department of Medicine, Budapest, Hungary.

The results of 43 interferon treatments of 35 patients (23 male, 12 female) are reported. The duration of the treatment was 6-18 months, the dose of interferon was 3x3-5 MU weekly. Complete response (HCV RNA became negative) was found in 11, relapse was observed in 3 patients. Partial response (transaminase levels became normal, or less than twice normal value, but patients remained HCV RNA positive) occurred in 23 cases, relapse was obeserved in 16. The therapy had no effect in 9 cases. The higher dose and longer term interferon therapy resulted in a higher rate of response to the treatment and a reduction in the number of relapses.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11173586&dopt=Abstract [PubMed - as supplied by publisher]

Pathol Oncol Res. 1997;3(1):44-46.
Immunologic Profile of Patients Suffering from Herpes Simplex Virus (HSV) -Associated Oral Lesions Treated with Natural Human Interferon Alpha (Egiferon).

Kovesi G, Paloczi K, Onody K, Fekete B.

Semmelweis University of Medicine, Department of Maxillofacial Surgery, Budapest, Hungary.

10 consecutive patients with HSV-associated chronic oral lesions were treated with Egiferon for ten days. There were a statistically significant increase in the Large Granule Lymphocyte (LGL) counts and the number of spontaneous E rosette forming cells by the end of the treatment period. Interferon alpha brought about a preferential expression of CD8, CD11b, CD14, CD25 and CD45RO cell surface molecules without any effect on the expression of CD2, CD3, CD4, CD20 and HLA-DR.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11173624&dopt=Abstract [PubMed - as supplied by publisher]

Gastroenterol Clin Biol. 2000 Dec;24(12):1191-6.
[Tumor escape mechanism involving Fas and Fas-L molecules in human colorectal tumors]

[Article in English, French]

Radfar S, Martin H, Tilkin-Mariame AF.

INSERM Unite 395 "Reponse immunitaire et complexe majeur d'histocompatibilite", CHU Purpan, Toulouse, France.

OBJECTIVES: The interaction between Fas and its ligand (Fas-L) leads to Fas-positive cell apoptosis. Our objective was to study a new mechanism of tumor escape involving these molecules, the so-called "counterattack". METHODS: We used flow cytometry to analyze Fas expression and apoptosis sensitivity in different human colorectal tumor cell lines. The presence of Fas-L mRNA was analyzed by RT-PCR. We studied apoptosis rate in peripheral blood lymphocytes and lymph node lymphocytes from patients with colorectal cancer by flow cytometric cell cycle analysis after in vitro culture with or without tumor cells. RESULTS: We found differences in Fas expression and sensitivity to Fas-induced apoptosis between different colorectal tumor cell lines. Interferon-gamma was also found to affect Fas expression and apoptosis sensitivity induced by an anti-Fas antibody. Actinomycin-D decreased Fas expression and apoptosis sensitivity in certain cell lines. Our data confirmed the tumor cell "counterattack" hypothesis by showing their capacity to induce apoptosis in lymphocytes from patients with colorectal cancer. CONCLUSION: Fas expression and apoptosis sensitivity in colorectal tumor cell lines can be modulated by actinomycin-D or interferon-gamma. These data may suggest new therapeutic options based on increased Fas expression in tumor cells induced by interferon-gamma, or on apoptosis induction in tumor cells with a local intratumoral treatment with actinomycin-D.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11173732&dopt=Abstract

Digestion. 2001;63(1):61-8.
Intestinal proliferation and delayed intestinal transit in a patient with a GLP-1-, GLP-2- and PYY-producing neuroendocrine carcinoma.

Byrne MM, McGregor GP, Barth P, Rothmund M, Goke B, Arnold R.

Department of Gastroenterology and Endocrinology, Philipps University, Baldingerstrasse, D-35033 Marburg, Germany. byrneailer.uni-marburg.de

Glucagon-like peptides (GLP) 1 and 2 are hormones derived from the post-translational processing of proglucagon in the intestinal L cells that influence intestinal motility and small bowel growth, respectively. We describe a patient with a neuroendocrine tumor of unknown primary origin with peritoneal carcinomatosis and diffuse liver metastases, who presented with constipation and nocturnal itching for over 3 years. Small bowel follow-through showed decreased small intestinal motility and marked intestinal hypertrophy. Biopsies from mesenterial lymph nodes showed, histologically, a well-differentiated neuroendocrine tumor (G1), with positive immunostaining for chromogranin A, GLP-1, GLP-2 and polypeptide YY (PYY). Jejunal biopsy demonstrated marked intestinal mucosal hypertrophy. HPLC analysis combined with RIA of tumor and serum extracts revealed that the tumor was producing and releasing fasting levels of GLP-1 of 738+/-20.7 pg/ml (normal levels (nl) <100 pg/ml), GLP-2 of 3,150+/-9 pg/ml (nl <100 pg/ml) as well as PYY 550 pg/ml (nl <100 pg/ml). Octreotide administration decreased levels of GLP-1 and GLP-2 and reduced small intestinal transit time from 150 to 50 min. However, tumor growth was not inhibited by octreotide, interferon or dacarbazine therapy and the patient died 8 months later. This is the first case report demonstrating the overproduction of GLP-1, GLP-2 and PYY from an neuroendocrine tumor, in a patient with intestinal hypertrophy and delayed intestinal transit time. 2001 S. Karger AG, Basel

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11173902&dopt=Abstract

Hair growth is a sophisticated biological process, which is still not thoroughly understood. A multitude of therapeutic measures, including drugs, surgery, and suppelements have been made available, and used. However, due to the diversity of the problems underlying hair loss, there is no single solution for all hair loss cases. Most of chemical drugs and hair transplantation surgeries are not free from varying degrees of undesirable side effects on health.

Hair Million is an alternative solution to cope with hair loss problems. Anecdotally, it shows prositive results and improvement especially for age-related hair thinning and hair loss for a fraction of people who take it. We do not know the mechanisms of action as to how Hair Million works to help stop hair loss, and promote hair growth. We only know by anecdotal observations. There has been no clinical trials nor placebo controlled statistical analysis on the efficacy of Hair Million on hair loss and hair growth.

DreamPharm Online Healthy Supplements || Constipation relief, laxative, colon cleansing || Lutein || Progesterone Cream || Natural herbal formula for hair loss problems ||